U.S. Large And Small-scale Bioprocessing Market To Reach $67.34 Billion By 2033

U.S. Large And Small-scale Bioprocessing Market Growth & Trends

The U.S. large and small-scale bioprocessing market size is projected to reach USD 67.34 billion by 2033, growing at a CAGR of 11.24% during the forecast period, according to a new report by Grand View Research, Inc. The U.S. large and small-scale bioprocessing industry is experiencing rapid growth, driven by the increasing demand for biologics, cell and gene therapies, and vaccines.

Advancements in single-use technologies, automation, and continuous processing are enhancing production efficiency, scalability, and flexibility across the industry. Additionally, growing investments in biomanufacturing infrastructure, rising R&D activities, and the expansion of CDMOs are supporting market expansion. Regulatory support and a strong clinical pipeline are further contributing to the market’s momentum, positioning the U.S. as a key hub for innovative bioproduction solutions.

The expansion of cell and gene therapy pipelines, along with accelerated clinical trials, is driving demand for flexible and scalable bioprocessing solutions. These advanced therapies require specialized, small-batch manufacturing with high precision, pushing biopharma companies to adopt innovative technologies and modular systems. This trend is significantly contributing to the growth of both large- and small-scale bioproduction infrastructure in the U.S. market.

In addition, the growing emphasis on personalized medicine is driving demand for small-scale, flexible bioprocessing systems that can accommodate patient-specific therapies. This shift toward precision treatments requires rapid, adaptable manufacturing setups, supporting the adoption of modular facilities and single-use technologies across the U.S. bioprocessing landscape.

However, high capital investment and operating costs remain a major restraint in the U.S. bioprocessing market. Establishing and maintaining large-scale bioproduction facilities involves substantial upfront infrastructure spending, along with ongoing expenses for equipment, validation, utilities, and skilled labor. These financial barriers can deter smaller biotech firms and startups from entering or scaling operations, often making them reliant on outsourcing or partnerships to access necessary manufacturing capabilities.

 Request a free sample copy or view report summary: U.S. Large And Small-scale Bioprocessing Market Report

U.S. Large And Small-scale Bioprocessing Market Report Highlights

• By scale, industrial scale dominated the U.S. large and small-scale bioprocessing industry in 2024. This dominance is driven by high-volume biologics production, established infrastructure, and strong investment from major biopharma manufacturers.

• The small-scale segment is anticipated to grow at the fastest CAGR from 2025 to 2033.

• By workflow, downstream processing dominated the market in 2024 and is anticipated to grow at the fastest CAGR of 12.46% over the forecast period. This is attributed to the rising need for efficient purification, filtration, and concentration technologies to ensure product quality and regulatory compliance.

• The fermentation workflow segment is anticipated to grow at a significant CAGR from 2025 to 2033.

• By product, bioreactors/fermenters dominated the market with a revenue share of 29.11% in 2024. This is attributed to their critical role in cell cultivation and microbial fermentation, supported by increasing adoption of single-use systems and demand for scalable, high-efficiency production platforms. However, cell culture products are anticipated to grow at a significant CAGR from 2025 to 2033.

• By application, biopharmaceuticals dominated the market in 2024, accounting for 63.54% market share and further anticipated to grow at the fastest growth rate over the forecast period. This is driven by the expanding pipeline of biologics, increasing demand for monoclonal antibodies, and advancements in cell and gene therapies.

• The speciality industrial chemicals application segment is expected to grow exponentially over the forecast period.

• By use-type, the multi-use segment dominated the U.S. market in 2024. This dominance is primarily due to its suitability for large-scale, high-throughput production, long-term cost efficiency, and established integration within legacy biomanufacturing systems.

• The single-use type segment is anticipated to grow at the fastest CAGR from 2025 to 2033.

• By mode, the in-house dominated the U.S. large and small-scale bioprocessing industry in 2024. This is attributed to greater control over production quality, intellectual property protection, and the presence of well-established infrastructure among leading biopharmaceutical companies.

• The outsourced mode segment is anticipated to grow at the fastest CAGR from 2025 to 2033.

U.S. Large And Small-scale Bioprocessing Market Segmentation

Grand View Research has segmented the U.S. large and small-scale bioprocessing market based on scale, workflow, product, application, use-type, and mode:

U.S. Large And Small-scale Bioprocessing Scale Outlook (Revenue, USD Million, 2021 - 2033)

• Industrial Scale (Over 50,000 Liter)

• Small Scale (Less Than 50,000 Liter)

U.S. Large And Small-scale Bioprocessing Workflow Outlook (Revenue, USD Million, 2021 - 2033)

• Downstream Processing

• Fermentation

• Upstream Processing

U.S. Large And Small-scale Bioprocessing Product Outlook (Revenue, USD Million, 2021 - 2033)

• Bioreactors/Fermenters

• Cell Culture Products

• Filtration Assemblies

• Bioreactors Accessories

• Bags & Containers

• Others

U.S. Large And Small-scale Bioprocessing Application Outlook (Revenue, USD Million, 2021 - 2033)

• Biopharmaceuticals

• Speciality Industrial Chemicals

• Environmental Aids

U.S. Large And Small-scale Bioprocessing Use-Type Outlook (Revenue, USD Million, 2021 - 2033)

• Multi-Use

• Single-Use

U.S. Large And Small-scale Bioprocessing Mode Outlook (Revenue, USD Million, 2021 - 2033)

• In-House

• Outsourced

List of Key Players in the U.S. Large And Small-scale Bioprocessing Market

• Merck KGaA (MilliporeSigma)

• Thermo Fisher Scientific, Inc.

• Danaher (Cytiva)

• Corning Inc.

• Sartorius AG

• Lonza

• Eppendorf AG

• Getinge AB

• PBS Biotech, Inc.

• Meissner Filtration Products, Inc.

• Entegris

• Saint-Gobain

• Repligen Corporation

• Avantor, Inc.

• Distek, Inc.

• F. Hoffmann-La Roche Ltd

• Bio-Synthesis, Inc.